Circadian Mechanisms, Glucose, and CV Risks in T1D
ConditionType 1 Diabetes (T1D)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorUniversity of Illinois at Chicago
About this trial
People with type 1 diabetes are disproportionately affected by cardiovascular disease (CVD). Short and irregular sleep have been associated with cardiovascular risk in this population. Improving sleep regularity has been associated with improved glycemic markers however mechanisms by which improving sleep regularity improves metabolic and cardiovascular health is not known. The investigators propose to conduct a mechanistic study using a sleep stability manipulation. This proposal will advance the understanding of mechanisms by which improving sleep regularity influences glycemic control and cardiovascular risk in T1D.
Eligibility criteria
Qualifiers
Adults 18-50 years with a clinical diagnosis of T1D for at least one year
Report habitual sleep irregularity ≥1 hour/week
Desire to improve sleep, and own a smartphone (Android or iPhone)
Disqualifiers
Self-reported A1C within the past 6 months ≥10%
insomnia symptoms defined as Insomnia Severity Index score ≥15
history of restless leg syndrome
history of severe hypoglycemia (defined as hypoglycemic episode that results in loss of consciousness, seizure, or requiring emergency room visit or hospitalization) within the past 6 months
Trial design
Treatments tested in this trial
- Sleep stability intervention
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Illinois at Chicago
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov